ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
COVID-19 and tuberculosis: the double whammy of respiratory pathogens.
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Systematic review and meta-analysis of Tuberculosis and COVID-19 Co-infection: Prevalence, fatality, and treatment considerations.PLoS neglected tropical diseases · 2024Pooled it
- Prevalence of Long COVID inJournal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- COVID-19 as a Potential Trigger for Tuberculosis: Insights From a Large-Scale Japanese Insurance Database Analysis.Journal of general and family medicine · 2026Article
- Lived experiences of tuberculosis patients accessing treatment during COVID-19 in Zimbabwe.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2026Article
- Characterization and anti-tuberculosis effects of γδ T cells expanded and activated byVirulence · 2025Review
- Review
- Global, regional, and national characteristics of the main causes of increased disease burden due to the covid-19 pandemic: time-series modelling analysis of global burden of disease study 2021.BMJ (Clinical research ed.) · 2025Article
- Comprehensive Spatial Investigation of Tuberculosis Dynamics and Affecting Factors in Şanlıurfa, Türkiye (2016-2023).GeoHealth · 2025Article
- Early preclinical development ofiScience · 2025Article
- Short- and long-term increased risk of all-cause mortality in a tuberculosis cohort attributed to SARS-CoV-2 infection: a time-dependent survival analysis in Chile.Lancet regional health. Americas · 2025Article
- Tuberculosis mortality and drug resistance among patients under TB treatment before and during COVID-19 in Burundi: a case-control study.BMC infectious diseases · 2025Article
- Post-COVID-19 tuberculosis in southeastern Spain: incidence, risk factors and the role of latent tuberculosis infection screening.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Article
- Difference of SARS-CoV-2 infection and influence factors between people with and without HIV infection.BMC public health · 2025Article
- Exploring the multilayered response of TB bacterium Mycobacterial tuberculosis to lysosomal injury.FEMS microbiology reviews · 2025Review
- Association of clinical laboratory parameters with latent tuberculosis infection among healthcare workers of primary health centers-A cross-sectional observational study.PLOS global public health · 2025Article
- Predicting the Incidence Rate of Tuberculosis in Western Iran Using Time Series Models Before and After COVID-19.Medical journal of the Islamic Republic of Iran · 2025Article
- Applying Multiple Analyses to Quantify Changes in the Global, Regional, and National Burden of Tuberculosis From 1990 to 2021 and the Forecast Until 2035.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Individuals with latent tuberculosis in a high TB endemic country show mild COVID-19.PloS one · 2025Article
- Drug resistance profiles ofJAC-antimicrobial resistance · 2024Article
- Integrating SARS-CoV-2 rapid antigen testing in maternal, neonatal and child health, HIV, and TB clinics in Kenya and Cameroon: outcomes from the Catalysing COVID-19 Action Project.BMJ public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prior to coronavirus disease 2019 (COVID-19), tuberculosis (TB) was the worst killer among infectious diseases. The union of these two obnoxious respiratory diseases can be devastating, with severe public health implications. The COVID-19 pandemic has affected all TB-elimination programmes due to the severe burden on healthcare systems and the diversion of funds and attention towards controlling the pandemic. The emerging data show that the COVID-19 pandemic caused a marked decrease in case notifications and bacille Calmette-Guérin immunisations, ultimately promoting disease transmission and increasing the susceptible population. The similarity between the clinical characteristics of TB and COVID-19 adds to the public health complications, with evidence of immune dysregulation in both cases leading to severe consequences. Clinical evidence suggests that severe acute respiratory syndrome coronavirus 2 infection predisposes patients to TB infection or may lead to reactivation of latent disease. Similarly, underlying TB disease can worsen COVID-19. Treatment options are limited in COVID-19; therefore, using immunosuppressive and immunomodulatory regimens that can modulate the concomitant bacterial infection and interaction with anti-TB drugs requires caution. Thus, considering the synergistic impact of these two respiratory diseases, it is crucial to manage both diseases to combat the syndemic of TB and COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.